All In MedTech

Device Trial Radar · NCT04720235

A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit

A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects

Last checked: Nov 20, 2026Latest source record: Apr 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

304

Actual

Start

Dec 9, 2020

Primary completion

Mar 9, 2021

Study completion Mar 30, 2021

Sponsor

Lead sponsor
Lucira Health IncNot on our public-company list
Sponsor type
Industry
First posted
Jan 22, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 14 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the performance of the FDA EUA authorized Lucira COVID-19 All-In-One Test Kit for the qualitative detection of SARS-CoV-2 virus in nasal swab samples as compared to a known high sensitivity EUA RT-PCR among asymptomatic individuals. The comparator assay for this study is the Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay.

Conditions

  • Covid19
  • Corona Virus Infection

Interventions

  • Lucira COVID-19 All-In-One test kitDevice

    The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA. Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider. Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. COVID-19 Prevalence Rate / Expected Values countsTime frame: 3 months

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neeraj Kochhar Family Medicine

    Los Gatos, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.